Nascent Pharma Holdings (NASC)
OTHER OTC:NASC
Want to see NASC full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Industry Trends
Favorable industry trends, such as increased legalization and consumer interest, provide a supportive backdrop for Can B's growth and market penetration efforts.
Negative Factors
Revenue Decline
Declining revenue trends indicate potential market share loss and operational inefficiencies, challenging Can B's growth prospects and competitive positioning.
Read all positive and negative factors
Positive Factors
Negative Factors
Industry Trends
Favorable industry trends, such as increased legalization and consumer interest, provide a supportive backdrop for Can B's growth and market penetration efforts.
Read all positive factors
Nascent Pharma Holdings (NASC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.08M
Dividend YieldN/A
Average Volume (3M)35.25K
Price to Earnings (P/E)―
Beta (1Y)-0.99
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,841,990
10 Day Avg. Volume42,355
30 Day Avg. Volume35,253
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap8.82
Enterprise Value/Revenue9.26
Enterprise Value/Gross Profit-6.01
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nascent Pharma Holdings Business Overview & Revenue Model
Company Description
Nascent Pharma Holdings, Inc. engages in the protection and commercialization of cannabis patents. It produces superfood drink mix products under the Longevity brand name. The company was formerly known as Can B Corp. and changed its name to Nasce...
How the Company Makes Money
Can B Corp generates revenue primarily through the sale of its hemp-derived products, which are distributed both through direct-to-consumer channels and wholesale distribution networks. The company leverages e-commerce platforms to reach a broad c...
Nascent Pharma Holdings Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.03M | 0.00 | 2.16M | 6.69M | 4.60M | 1.71M |
| Gross Profit | -1.59M | -742.32K | 358.70K | 2.61M | 2.99M | 1.43M |
| EBITDA | -9.99M | -7.65M | -5.82M | -12.59M | -9.52M | -7.16M |
| Net Income | -13.26M | -10.20M | -9.74M | -14.92M | -12.17M | -8.88M |
Balance Sheet | ||||||
| Total Assets | 1.86M | 299.54K | 10.13M | 15.56M | 16.47M | 3.91M |
| Cash, Cash Equivalents and Short-Term Investments | 7.88K | 5.96K | 34.01K | 73.19K | 449.00K | 457.80K |
| Total Debt | 9.01M | 8.30M | 9.18M | 9.34M | 7.28M | 2.08M |
| Total Liabilities | 11.64M | 13.02M | 11.13M | 12.86M | 10.86M | 2.44M |
| Stockholders Equity | -9.79M | -12.72M | -1.00M | 2.70M | 5.62M | 1.48M |
Cash Flow | ||||||
| Free Cash Flow | 246.61K | -221.63K | -1.32M | -3.95M | -8.04M | -2.00M |
| Operating Cash Flow | 246.61K | -221.63K | -1.30M | -3.95M | -7.32M | -1.95M |
| Investing Cash Flow | -9.97K | 231.32K | -84.63K | 0.00 | -860.79K | -25.25K |
| Financing Cash Flow | -259.94K | -27.82K | 1.35M | 3.57M | 8.17M | 2.38M |
Nascent Pharma Holdings Technical Analysis
Negative
0.01
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
44.95
Neutral
-40.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NASC, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.95 is Neutral, neither overbought nor oversold. The STOCH value of -40.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NASC.
Nascent Pharma Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.08M | -0.29 | ― | ― | ― | ― | |
46 Neutral | $1.69M | -1.53 | 2.66% | ― | -22.44% | -100.02% | |
45 Neutral | $21.32M | -1.06 | -43.00% | ― | -8.49% | 72.59% | |
45 Neutral | $5.24M | ― | ― | ― | ― | ― | |
42 Neutral | $1.60M | ― | ― | ― | ― | ― | |
| ― | $3.92M | -0.28 | -9999.00% | ― | ― | 85.99% |
* Healthcare Sector Average
NASC
Nascent Pharma Holdings
0.01
-0.02
-61.11%
CPHI
China Pharma Holdings
0.53
-1.46
-73.57%
RDHL
RedHill Biopharma
1.01
-0.97
-48.99%
PRFX
PainReform
1.90
-7.80
-80.41%
UPC
Universe Pharmaceuticals
3.00
-1.78
-37.24%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.71
-6.05
-89.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―